S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Fund/Baker Bros Advisors/Q3 2025

Baker Bros Advisors

Periodo: Q3 2025 · Depositato: 2025-11-14
Vedi su SEC EDGAR
AUM
$13.84B
Valore totale del portafoglio
Posizioni
91
Titoli dichiarati
Prima Posizione
ONC
21.7% $3.00B
Var. Trimestrali
+8 / -8
nuovi · usciti
⚠️Informativa sui Depositi 13F

I dati AUM mostrati sono calcolati sommando il valore di mercato dichiarato di tutte le posizioni nei depositi SEC 13F-HR — non rappresentano il patrimonio effettivo gestito dal fondo.

  • Escluse liquidità, obbligazioni, private equity, posizioni corte e azioni estere non soggette all'obbligo di dichiarazione.
  • Per le opzioni PUT e CALL, il Valore dichiarato è il valore nozionale delle azioni sottostanti — non il premio pagato. Ciò sovrastima significativamente il capitale effettivamente a rischio.
  • Il patrimonio reale del fondo è tipicamente superiore e include strategie, strumenti e posizioni che non compaiono mai in un 13F.
  • I depositi 13F riguardano i gestori istituzionali con ≥$100M in titoli 13F. Le posizioni riflettono le partecipazioni a fine trimestre, divulgate entro 45 giorni dalla fine del periodo.

Dati provenienti da SEC EDGAR. Questo tracker è a scopo puramente informativo e non costituisce consulenza finanziaria.

Partecipazioni in Portafoglio

Prime 30 posizioni

⚠️ Performance % calcolata dalla data di deposito ( 2025-11-14) si riferisce al titolo sottostante — non al P&L del derivato.
TickerEmittenteNozionalePortafoglio %Al DepositoOra (Fine Giornata)Dal DepositoAllocazione
ONCBeOne Medicines Ltd.$3.00B21.66%$340.70$297.65-12.6%
21.7%
INCYIncyte Corporation$2.61B18.84%$84.81$116.86+37.8%
18.8%
MDGLMadrigal Pharmaceuticals, Inc.$982.3M7.10%$458.66$528.10+15.1%
7.1%
INSMInsmed Incorporated$965.4M6.98%$144.01$111.60-22.5%
7.0%
ACADACADIA Pharmaceuticals Inc.$915.4M6.61%$21.34$25.97+21.7%
6.6%
SMMTSummit Therapeutics Inc.$696.7M5.03%$20.66$15.42-25.4%
5.0%
RYTMRhythm Pharmaceuticals, Inc.$566.0M4.09%$100.99$114.17+13.1%
4.1%
RVMDRevolution Medicines, Inc.$441.6M3.19%$46.70$189.24+305.2%
3.2%
CELCCelcuity Inc.$391.0M2.83%$49.40$107.95+118.5%
2.8%
KYMRKymera Therapeutics, Inc.$376.5M2.72%$56.60$113.51+100.5%
2.7%
KODKodiak Sciences Inc.$283.4M2.05%$16.37$38.54+135.4%
2.0%
ALKSAlkermes plc$242.7M1.75%$30.00$54.58+81.9%
1.8%
ABCLAbCellera Biologics Inc.$138.4M1.00%$5.03$8.11+61.2%
1.0%
EWTXEdgewise Therapeutics, Inc.$118.5M0.86%$16.22$39.56+143.9%
0.9%
KNSAKiniksa Pharmaceuticals International, plc$109.7M0.79%$38.83$64.53+66.2%
0.8%
STOKStoke Therapeutics, Inc.$108.9M0.79%$23.50$32.70+39.1%
0.8%
IMTXImmatics N.V.$103.0M0.74%$8.52$9.95+16.8%
0.7%
GRALGRAIL, Inc.$96.4M0.70%$59.13$69.11+16.9%
0.7%
IDYAIDEAYA Biosciences, Inc.$89.1M0.64%$27.21$37.65+38.4%
0.6%
IMVTImmunovant, Inc.$88.0M0.64%$16.12$38.79+140.6%
0.6%
IMCRImmunocore Holdings plc$84.4M0.61%$36.33$32.50-10.5%
0.6%
BCYCBicycle Therapeutics plc$84.3M0.61%$7.74$4.35-43.8%
0.6%
RAREUltragenyx Pharmaceutical Inc.$83.4M0.60%$30.08$33.47+11.3%
0.6%
ABVXAbivax S.A.$74.4M0.54%$84.90$144.65+70.4%
0.5%
ARWRArrowhead Pharmaceuticals, Inc.$57.6M0.42%$34.49$83.99+143.5%
0.4%
ROIVRoivant Sciences Ltd.$57.0M0.41%$15.13$35.13+132.2%
0.4%
DNLIDenali Therapeutics Inc.$54.2M0.39%$14.52$25.83+77.9%
0.4%
MRUSMerus N.V.$54.1M0.39%
0.4%
NTLAIntellia Therapeutics, Inc.$47.4M0.34%$17.27$17.56+1.7%
0.3%
REPLReplimune Group, Inc.$46.3M0.33%$4.19$11.58+176.4%
0.3%

Attività Trimestre su Trimestre

Q3 2025 vs. Q2 2025

Nuove Posizioni (8)

TickerEmittenteNozionaleDal Deposito
ABVXAbivax S.A.$74.4M+70.4%
Celcuity Inc.$40.9M
IONSIonis Pharmaceuticals, Inc.$37.1M
RNAMAvidity Biosciences, Inc.$27.2M
VKTXViking Therapeutics, Inc.$9.6M
PHVSPharvaris N.V.$9.4M
HRTXHeron Therapeutics, Inc.$5.4M
MBXMBX Biosciences, Inc.$4.9M

Posizioni Chiuse (8)

TickerEmittenteNozionale
VRNAVerona Pharma plc$21.2M
VERVVerve Therapeutics, Inc.$19.0M
BPMCBlueprint Medicines Corporation$16.1M
IGMSIGM Biosciences, Inc.$4.6M
FATEFate Therapeutics, Inc.$2.8M
CADLCandel Therapeutics, Inc.$1.8M
RCKTRocket Pharmaceuticals, Inc.$1.4M
HOOKHOOKIPA Pharma Inc.$1.0M

Aumentate (8)

TickerEmittenteNozionaleVar. AzioniDal Deposito
RAPPRapport Therapeutics, Inc.$39.7M+181.2%
ARWRArrowhead Pharmaceuticals, Inc.$42.8M+77.9%+143.5%
XNCRXencor, Inc.$7.7M+64.4%
SYRESpyre Therapeutics, Inc.$7.4M+59.6%
IDYAIDEAYA Biosciences, Inc.$44.6M+54.6%+38.4%
VTVTvTv Therapeutics, Inc.$2.0M+52.4%
CELCCelcuity Inc.$318.3M+45.2%+118.5%
ALKSAlkermes plc$59.3M+26.2%+81.9%

Ridotte (5)

TickerEmittenteNozionaleVar. AzioniDal Deposito
CTNMContineum Therapeutics, Inc.$-0.3M-75.1%
GPCRStructure Therapeutics Inc.$-8.5M-38.0%
CERSCerus Corporation$-2.3M-22.3%
KALAKALA BIO, Inc.$-4.2M-18.0%
INSMInsmed Incorporated$189.1M-13.1%-22.5%
Torna agli Hedge Fund